Perspective Therapeutics CATX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.19M+30.1% | -$37.49M-44.4% | -$25.97M-20.9% | -$21.49M-18.2% | -$18.18M+54.7% | ||
| $1.13M+11.4% | $1.01M+30.5% | $775K+5.7% | $733K+0.1% | $732K+3.2% | ||
| $2.55M+10.6% | $2.31M+7.1% | $2.16M-10.3% | $2.4M+14.5% | $2.1M+1.8% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $52K+130% | -$173K-276% | -$46K-131% | $147K+487% | -$38K+82.5% | ||
| —— | —— | $0— | $0— | $0— | ||
| -$4.21M— | —— | $5.54M+295% | -$2.84M-65.8% | -$1.71M— | ||
| -$3.61M-564% | $778K-53.5% | $1.67M-21.2% | $2.13M+183% | -$2.57M-180% | ||
| $327K+187% | -$375K— | $0+100% | -$19K+92.1% | -$240K-126% | ||
| $51K+15.9% | $44K-24.1% | $58K-58.3% | $139K+54.4% | $90K+63.6% | ||
| -$78K— | —— | -$14K+83.3% | -$84K+39.1% | -$138K— | ||
| $0— | —— | —— | —— | -$1.4M— | ||
| $392K— | —— | $19K-91.0% | $212K+186% | $74K-91.6% | ||
| -$31.47M-27.6% | -$24.66M-51.3% | -$16.29M+18.3% | -$19.95M+7.5% | -$21.58M+18.9% | ||
| $6.86M+35.1% | $5.08M+155% | $1.99M+94.2% | $1.03M-78.0% | $4.66M-68.1% | ||
| $150.34M+629% | $20.61M-35.8% | $32.13M-27.8% | $44.49M+96.8% | $22.6M-86.3% | ||
| $47.64M+140% | -$119.67M-349% | $48.15M-3.3% | $49.82M+130% | $21.7M-72.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$109.55M-484% | $28.54M+104% | $13.99M+228% | $4.26M+177% | -$5.57M+96.0% | ||
| $15K+15.4% | $13K0.0% | $13K0.0% | $13K0.0% | $13K+8.3% | ||
| $290K— | $0-100% | $226K+55.9% | $145K— | $0-100% | ||
| $164.36M— | $0-100% | $213K+61.4% | $132K-98.7% | $9.97M+2,791% | ||
| $23.34M— | —— | -$2.09M+86.6% | -$15.56M+9.4% | -$17.17M— | ||
| —— | $10M— | —— | —— | —— | ||
| $392K— | —— | $19K-91.0% | $212K+186% | $74K-91.6% | ||
| $0— | —— | —— | —— | -$1.4M— | ||
| -$3.61M-564% | $778K-53.5% | $1.67M-21.2% | $2.13M+183% | -$2.57M-180% | ||
| $51K+15.9% | $44K-24.1% | $58K-58.3% | $139K+54.4% | $90K+63.6% | ||
| $327K+187% | -$375K— | $0+100% | -$19K+92.1% | -$240K-126% | ||
| -$78K— | —— | -$14K+83.3% | -$84K+39.1% | -$138K— | ||
| $0-100% | $51K+30.8% | $39K+8.3% | $36K+300% | $9K-81.3% | ||
| $47.64M-12.2% | $54.28M+12.7% | $48.15M-3.3% | $49.82M+130% | $21.7M— | ||
| $15K+15.4% | $13K0.0% | $13K0.0% | $13K0.0% | $13K+8.3% | ||
| $10.15M— | —— | —— | —— | $0— | ||
| $1.25M+510% | $205K— | $0— | $0— | $0— | ||
| -$38.33M-28.9% | -$29.73M-62.6% | -$18.28M+12.8% | -$20.98M+20.0% | -$26.24M+36.3% | ||
| -$38.33M-28.9% | -$29.73M-62.6% | -$18.28M+12.8% | -$20.98M+20.0% | -$26.24M+36.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Perspective Therapeutics generate?
- Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
- What is Perspective Therapeutics's free cash flow?
- After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
- Where does Perspective Therapeutics's cash flow data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
